Discussion Day

Pioneering the Next Generation of CD3 Bispecifics

9:00

Chair’s Opening Remarks

Patrick Baeuerle 
Managing Director
MPM Capital

9:15 

Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3-Bispecifics and CAR T Cells

• Two competing platforms exist for redirecting T cells to recognize and kill
tumors: Bispecific antibodies and chimeric antigen receptor (CAR) T cells
• We have developed pre-clinical in vitro and in vivo models to
mechanistically compare these two technologies and will discuss our
findings as well as the clinical implications

David DiLillo
Senior Staff Scientist
Regeneron

9:45

10:30

Speed Networking

Morning Refreshments

11:00

Panel Discussion: Contrasting Bispecific Therapeutics & CAR-T Approaches

• Evaluating “off-the-shelf” vs personalized therapies
• Understand how these contrasting approaches each manage safety for on target off tumor toxicities
• Investigating differences in terms of solid and liquid tumour targeting
• Are these therapeutics considered cures or just bridging therapies to the next breakthrough?

David DiLillo
Senior Staff Scientist
Regeneron

Eugene Zhukovsky
CSO
Biomunex

Tariq Ghayur
Senior Research Fellow
AbbVie

11:30

TriTAC: A Tri-Specific T Cell Engaging Platform for the Treatment of Solid Tumors

• TriTAC molecules contain three antibody domains: an anti-CD3 domain to bind to T cells, an anti-target domain to bind antigens on tumors cells, and
an anti-albumin domain to provide half-life extension.
• TriTAC molecules have potent directed T cell killing activity in vitro and in
vivo.
• HPN424, a TriTAC molecule targeting PSMA, is being tested in a Phase I clinical trial.
• HPN536, a MSLN targeting TriTAC, is in development

Rick Austin
Senior Director, Biology Research
Harpoon Therapeutics

12:00

Lunch & Networking

13:00

XPAT-T Cell Engagers: A Novel Format to Mitigate the On-Target, Off-Tumor Problem

XPATs represent a novel format of highly-selective bispecific T cell engagers
that are activated by proteases in the tumor microenvironment
• XTENylation provides long in vivo half-life and universal masking applicable
to any antibody.
• T cell activation of XPATs is attenuated >10,000-fold prior to local
proteolysis in the tumor microenvironment

Volker Schellenberger
President & CTO
Amunix

13:30

Development of Poly-Specific T-Cell Engagers & Immunomodulatory Molecules Using the DARPin Technology Platform

• The DARPin technology provides a versatile platform for generation of
polyspecific, multifunctional biotherapeutics with excellent biophysical
and easily controlled pharmaco-dynamic characteristics , low, if any, immunogenicity and desired biological properties
• Several DARPin based drug candidates are successfully progressing through
different stages of pre-clinical and clinical development

Victor Levitsky 
VP, Immuno-Oncology
Molecular Partners

14:00

Panel Discussion: Investigating Next Generation Cell Engaging Approaches

Rick Austin
Senior Director, Biology Research
Harpoon Therapeutics 

 

Volker Schellenberger
President & CTO
Amunix 

Victor Levitsky 
VP - Immunology
Molecular Partners

14:30

Roundtable Discussion: Evaluating the Criteria Essential to Success in the Increasingly Competitive CD3 Bispecific Field

Collectively discuss CD3 targeting approaches and share experiences in overcoming key challenges. Gain insights and perspectives from stakeholders at a range of different stages of development in the field and benchmark your progress against a variety of companies and organizations.

15:15

Chair’s Closing Remarks

Patrick Baeuerle
Managing Director
MPM Capital

15:30

Close of Discussion Day